# A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors

> **NCT06329206** · PHASE1 · RECRUITING · sponsor: **Suzhou Genhouse Bio Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** GH2616 Tablets

## Key facts

- **NCT ID:** NCT06329206
- **Lead sponsor:** Suzhou Genhouse Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2026-04-25
- **Final completion:** 2026-09-01
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329206, "A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06329206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*